EPO is effective in about 70% of patients with autoimmune hemolytic anemia

BestPractice | Jun 2019 | EHA 2019 |

Erythropoietin (EPO) has been anecdotally used in AIHA to ameliorate bone marrow response, but only one systematic series has been published and predictors of response are not known. In this MEDtalk Brune Fattizzo present, that use of EPO is effective in about 70% of AIHA patients unresponsive to ongoing/previous treatments, particularly in cases with inadequate reticulocytosis. Although preliminary, these data advise EPO use to stimulate bone marrow compensatory response